Table 2.

SARS-CoV-2 mAb Tested in Animal Models.

Antibody	Animal Model	Prophylactic	Therapeutic	Virus Dose	Outcome compared to control
2B04 (Alsoussi et al., 2020)	murine BALB/C+ hACE2-AdV (Hassan et al., 2020)	1 day prior to infection (IP) (~10 mg/kg)		4 x 105 PFU Intranasal	•Prevented weight loss •Reduced viral titers (Lung, 31-fold decrease; spleen, 11-fold decrease) •Diminished lung inflammation (histopathology)
2H04 (Alsoussi et al., 2020)	murine BALB/C+ hACE2-AdV (Hassan et al., 2020)	1 day prior to infection (IP) (~10 mg/kg)		4 x 105 PFU Intranasal	•Prevented weight loss •Reduced viral titers (Lung, 11-fold decrease; spleen, 6-fold decrease)
COV2-2196 COV2-2130 (Cocktail) COV2-2196+ COV2-2130 (Zost et al., 2020)	BALB/C + Mouse-Adapted SARS-CoV-2 (Dinnon et al., 2020)	1 day prior to infection (IP) (~10 mg/kg)		105 PFU Intranasal	•Reduced viral titers (Lung, 105- fold reduction)
	murine BALB/C+ hACE2-AdV (Hassan et al., 2020)	1 day prior to infection (IP) (~10 mg/kg)		4 x 105 PFU Intranasal	•Prevented weight loss •Lower viral titers (Lung, 20-fold decrease; spleen, 10-fold decrease; heart, 1000-fold) •Diminished lung inflammation (histopathology and cytokine)
COV2-2196 COV2-2381	Rhesus Macaques	1 day prior to infection (IV) (50 mg/kg)		105 PFU Intranasal and Intratracheal	•Reduced viral titers (Nasal swab, 107-fold decrease; BAL, 105- fold decrease)
COV2-2196 COV2-2130 (Cocktail) COV2-2196+ COV2-2130	BALB/C + Mouse-Adapted SARS-CoV-2 (Hassan et al., 2020)		12 h post-infection (~20 mg/kg)	106 PFU Intranasal	For 2196 and Cocktail: •Reduced viral titers (Lung, 106- fold reduction) For 2130: •No change in viral titers compared to mock
(Cocktail) COV2-2196+ COV2-2130	BALB/C+ hACE2-AdV (Hassan et al., 2020)		12 h post-infection (~20 mg/kg)	4 x 105 PFU Intranasal	•Reduced viral titers (Lung, 106 fold reduction) •Diminished lung inflammation (cytokine expression)
REGN-COV2 (REGN10987 + REGN10933) (Baum et al., 2020a)	Syrian Hamsters	2 day prior to infection (IP) (50, 5, and 0.5 mg/kg)		2.3 x 104 PFU Intranasal	All doses: •Prevented weight loss •Diminished lung inflammation (histopathology) For 50 and 5 mg/kg dose: •Reduced viral titers (Lung, 104-fold decrease)
	Syrian Hamsters		1 day post infection (IP) (50, 5, and 0.5 mg/kg)	2.3 x 104 PFU Intranasal	For 50 and 5 mg/kg doses: •Reduced weight loss
	Rhesus Macaques	3 day prior to infection (IV) (50 mg/kg)		105 PFU Intranasal and Intratracheal	For 50 mg/kg: •Reduced viral titers (Nasal swab, 106-fold reduction; BAL, 104- fold reduction)
	Rhesus Macaques	3 day prior to infection (IV) (0.3 and 50 mg/kg)		106PFU Intranasal and Intratracheal	For 50 mg/kg: •Reduced viral titers (Nasal swab, 106-fold reduction; BAL, 104- fold reduction) •Reduced histopathology For 0.3 mg/kg: •Reduced viral titers (Nasal swab) •Diminished lung inflammation (histopathology)
	Rhesus Macaques		1 day post infection (IP) (150 and 25 mg/kg)	105 PFU Intranasal and Intratracheal	For both 150 mg/kg and 25 mg/kg: •Reduced viral titers (Nasal swab, 103-fold reduction; BAL, 102- fold reduction) •Reduced histopathology
CCL12.1 (Rogers et al., 2020)	Syrian Hamsters	12 h pre-infection (IP) (16.5, 4.125, 1.03, 0.25, 0.06 mg/kg)		106PFU Intranasal	For 16.5, 4.125, and 1.03 mg doses: •Reduced viral titers (Lung, 105- reduction) For 16.5 and 4.125 doses: •Diminished weight loss
CB6 LALA (Shi et al., 2020b)	Rhesus Macaques	1 day prior to infection (IV) 50 mg/kg		105 TCID50 Intratracheal	•Reduced viral titers:(Throat swabs, viral RNA not detected) •Reduced histopathology
CB6 LALA	Rhesus Macaques		1 day and 3 post infection (IV) 50 mg/kg	105 TCID50 Intratracheal	•Reduced viral titers:(Throat swabs, 102-103 fold reduction) •Redudced histopathology
B38 (Wu et al., 2020d)	Murine hACE2 Transgenic		12 h post-infection (25 mg/kg)	NR	•Reduced Weight Loss •Reduced viral titers: Lung 102-fold •Reduced histopathology
H4 (Wu et al., 2020d)	Murine hACE2 Transgenic		12 h post-infection (25 mg/kg)	NR	•Reduced viral titers (Lung 102-fold decrease) •Reduced histopathology
CV07-209 (Kreye et al., 2020)	Syrian Hamsters	24 h prior (18 mg/kg)		105PFU Intranasal	•Prevented Weight Loss •Reduced viral titers (Lung 104 to 105-fold) •Reduced histopathology
	Syrian Hamsters		2 h post-infection (18 mg/kg)	105PFU Intranasal	•Prevented Weight Loss •Reduced viral titers: Lung 105-fold •Reduced histopathology
S2M11 S2E12 Cocktail (S2M11 + S2E12) (Tortorici et al., 2020)	Syrian Hamsters	48 h prior (1 or 0.5 mg/kg)		2x105 TCID50 Intranasal	All doses: •Reduced viral titers (Lung 104-fold decrease)
LY-CoV555 (Jones et al., 2020)	Rhesus Macaques	1 day prior to infection (IV) (50, 15, 2.5, and 1 mg/kg)		1.1x105 PFU Intranasal and Intratracheal	For all doses: •Reduced viral titers (BAL, nasal swab, oral swab)
ADG-2 (Rappazzo et al., 2021)	BALB/c + Mouse-Adapted SARS-CoV-2	12 h prior (10mg/kg)		103 PFU Intranasal	•Prevented weight loss •Reduced viral titers: Lung 107-fold •Reduced histopathology
	BALB/c + Mouse-Adapted SARS-CoV-2		12 h post-infection (10mg/kg)	103 PFU Intranasal	•Reduced weight loss •Reduced viral titers: Lung 104-fold •Reduced histopathology